Drug maker giant Merck shedding off prior controversial ventures of Vioxx has announced the acquisition of rival drug maker Schering-Plough for a whooping $41 billion. The new deal will help consolidate the drug industry more on a solid footing. Perhaps, this news is a blow for the sales and marketing force as that sector might experience some lay-off resulting from this consolidation effort.
The new force will be in terms more effective in bringing discovery to a quicker platform with a renewed work force and bigger talent pool of brilliant scientists. The healthcare industry will probably benefit more out of this with more drugs coming out from a single big pharmaceutical giant.
This new deal follows on the heals of the Pfizer - Wyeth and probably opens the door for the Roche - Genentech to fall into place.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment